Biofer v. Vifor: “Between 7.0 and 9.0” Means Maintained Throughout, Not Merely Reached
A case note on the Federal Circuit’s September 3, 2026 nonprecedential decision affirming a claim construction that resulted in judgment […]
September 11, 2026
Exelixis v. MSN: Two Polymorphs, a Fourteen-Form Genus, and the Limits of Written Description
A case note on the Federal Circuit’s August 31, 2026 decision affirming the validity of Exelixis’s crystalline cabozantinib (L)-malate claims